Week In Review: Xinbang Pharma Acquires Chinese Peptide Co. For $323 Million
May 09, 2015 at 16:54 PM EDT
Bayer AG announced that the CFDA has approved Xarelto (rivaroxaban), a once-daily oral anticoagulant, for two new anti-clotting indications: strokes and deep vein thrombosis.
